Literature DB >> 24128129

Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology.

Ayoma D Attygalle1, José Cabeçadas, Philippe Gaulard, Elaine S Jaffe, Daphne de Jong, Young Hyeh Ko, Jonathan Said, Wolfram Klapper.   

Abstract

Mature T-cell and T/NK-cell neoplasms are both uncommon and heterogeneous, among the broad category of non-Hodgkin lymphomas. Owing to the lack of specific genetic alterations in the vast majority, most currently defined entities show overlapping morphological and immunophenotypic features, and therefore pose a challenge to the diagnostic pathologist. In the light of recent immunophenotypic, cytogenetic and molecular genetics advances in the field of T-cell and T/NK-cell lymphomas, the focus of the lymphoma workshop of the European Association for Haematopathology/Society for Hematopathology meeting in Lisbon, Portugal, in October 2012 was to refine existing diagnostic criteria and clarify the borders between overlapping entities. The panel reviewed over 200 submitted cases, which were grouped into five categories: (i) angioimmunoblastic T-cell lymphoma and T-follicular-helper-cell-associated lymphomas; (ii) CD30-positive T-cell lymphomas/lymphoproliferative diseases; (iii) extranodal T-cell and NK-cell neoplasms; (iv) EBV-associated T-cell/NK-cell lymphomas/lymphoproliferative diseases; and (v) peripheral T-cell lymphoma, not otherwise specified, post-transplant lymphoproliferative disorders, and mimics. This report summarizes the discussions and conclusions of the workshop, which question current diagnostic criteria and provide recommendations for refining existing classifications.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD30; Epstein-Barr virus; T-cell lymphoma; angioimmunoblastic; follicular T-helper

Mesh:

Substances:

Year:  2013        PMID: 24128129      PMCID: PMC6364972          DOI: 10.1111/his.12251

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  40 in total

1.  Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.

Authors:  Rebecca L King; Linda N Dao; Ellen D McPhail; Elaine S Jaffe; Jonathan Said; Steven H Swerdlow; Christopher A Sattler; Rhett P Ketterling; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; Sarah E Gibson; Sarah L Ondrejka; Alina Nicolae; William R Macon; Surendra Dasari; Edgardo Parrilla Castellar; Andrew L Feldman
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

Review 2.  Diagnosis and classification of lymphoma: Impact of technical advances.

Authors:  Elaine S Jaffe
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

Review 3.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

4.  Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets.

Authors:  Laurence de Leval; Marie Parrens; Fabien Le Bras; Jean-Philippe Jais; Virginie Fataccioli; Antoine Martin; Laurence Lamant; Richard Delarue; Françoise Berger; Flavie Arbion; Céline Bossard; Marie-Christine Copin; Danielle Canioni; Frédéric Charlotte; Gandhi Damaj; Peggy Dartigues; Bettina Fabiani; Albane Ledoux-Pilon; Karine Montagne; Thierry Molina; Martine Patey; Patrick Tas; Michel Peoch; Barbara Petit; Tony Petrella; Jean-Michel Picquenot; Thérèse Rousset; Marie-Christine Rousselet; Isabelle Soubeyran; Sylvie Thiebault; Olivier Tournilhac; Luc Xerri; Christian Gisselbrecht; Corinne Haioun; Georges Delsol; Philippe Gaulard
Journal:  Haematologica       Date:  2015-06-04       Impact factor: 9.941

Review 5.  Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Authors:  Elaine S Jaffe; Paul M Barr; Sonali M Smith
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 6.  Peripheral T cell lymphoma in Asia.

Authors:  Sanghui Park; Young Hyeh Ko
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

Review 7.  Pathogenesis of Enteropathy-Associated T Cell Lymphoma.

Authors:  Udit Chander; Rebecca J Leeman-Neill; Govind Bhagat
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

8.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

9.  CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.

Authors:  Guillaume Lefèvre; Marie-Christine Copin; Christophe Roumier; Hélène Aubert; Martine Avenel-Audran; Nathalie Grardel; Stéphanie Poulain; Delphine Staumont-Sallé; Julien Seneschal; Gilles Salles; Kamel Ghomari; Louis Terriou; Christian Leclech; Chafika Morati-Hafsaoui; Franck Morschhauser; Olivier Lambotte; Félix Ackerman; Jacques Trauet; Sandrine Geffroy; Florent Dumezy; Monique Capron; Catherine Roche-Lestienne; Alain Taieb; Pierre-Yves Hatron; Sylvain Dubucquoi; Eric Hachulla; Lionel Prin; Myriam Labalette; David Launay; Claude Preudhomme; Jean-Emmanuel Kahn
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 10.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.